JP2015529652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529652A5 JP2015529652A5 JP2015524600A JP2015524600A JP2015529652A5 JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5 JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015524600 A JP2015524600 A JP 2015524600A JP 2015529652 A5 JP2015529652 A5 JP 2015529652A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- aryl
- deuterium
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C Chemical compound CCC(**1)=C(*2**(C)CCC(C)CCC3**CC2)C3=C1C(C)C(C)C 0.000 description 5
- YIINKKNBXUALQJ-CPPUAGTESA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(c2c3C4NC2CC(C)C4)ccc3-c(cc2)ccc2-c(cc2)cc3c2nc(C(CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O YIINKKNBXUALQJ-CPPUAGTESA-N 0.000 description 1
- LQKWQBFFAXGZOK-WPZYDENFSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)c(C(C3)N4C3(C)CC43)c3c2-c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O LQKWQBFFAXGZOK-WPZYDENFSA-N 0.000 description 1
- JWJIPZPFNNVDPQ-BSDZSUBPSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)c(C3N(C4C5)C5(C)C3)c4c2-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O JWJIPZPFNNVDPQ-BSDZSUBPSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210273491.8 | 2012-08-03 | ||
| CN201210273491 | 2012-08-03 | ||
| CN201310116933.2 | 2013-04-03 | ||
| CN201310116933 | 2013-04-03 | ||
| PCT/CN2013/000915 WO2014019344A1 (en) | 2012-08-03 | 2013-08-05 | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529652A JP2015529652A (ja) | 2015-10-08 |
| JP2015529652A5 true JP2015529652A5 (cg-RX-API-DMAC7.html) | 2016-09-23 |
Family
ID=50027184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524600A Pending JP2015529652A (ja) | 2012-08-03 | 2013-08-05 | Ｃ型肝炎阻害剤である架橋環化合物及びその医薬品への応用 |
Country Status (15)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201412709A (zh) | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| DK2909205T3 (en) | 2012-10-19 | 2017-03-06 | Bristol Myers Squibb Co | 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6502939B2 (ja) | 2013-11-22 | 2019-04-17 | シーエル バイオサイエンシズ リミティド ライアビリティ カンパニー | 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 |
| US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| CN104860935A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途 |
| CN105384792B (zh) * | 2014-08-23 | 2020-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016033164A1 (en) * | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| CN105693700B (zh) * | 2014-12-16 | 2019-01-04 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的桥环化合物及其制备方法 |
| TWI703141B (zh) * | 2015-03-12 | 2020-09-01 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的化合物及其在藥物中的應用 |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| EP3589633A1 (en) * | 2017-03-02 | 2020-01-08 | Wockhardt Limited | Heterocyclic derivatives as antibacterial compounds |
| EP3706740A4 (en) * | 2017-11-06 | 2021-07-28 | Suzhou Pengxu Pharmatech Co., Ltd. | METHOD FOR MANUFACTURING ACALABRUTINIB |
| US11634389B2 (en) | 2018-11-28 | 2023-04-25 | The Regents Of The University Of Michigan | Succinate dehydrogenase inhibitors and methods of making and using the same |
| US20220227729A1 (en) | 2019-05-21 | 2022-07-21 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CN111118073B (zh) * | 2019-12-27 | 2022-02-15 | 宜昌东阳光生化制药有限公司 | 酶法合成依米他韦中间体的方法 |
| CN114929228A (zh) * | 2020-01-03 | 2022-08-19 | 布鲁奥科制药有限公司 | 用于治疗cns病症的化合物和组合物 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| GB202013383D0 (en) * | 2020-08-26 | 2020-10-07 | Givaudan Sa | Process |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3019259A (en) * | 1959-11-02 | 1962-01-30 | Dow Chemical Co | 1, 4-dihydro-1, 4-methanonaphthalene-5, 8-diamine |
| US3268581A (en) * | 1964-05-08 | 1966-08-23 | Dow Chemical Co | Anthraquinone dialkanesulfonimide |
| US3493616A (en) * | 1967-02-27 | 1970-02-03 | Universal Oil Prod Co | Hydroxy and/or hydrocarbyloxy and amino-alkano-tetrahydronaphthalenes |
| US3835104A (en) * | 1968-09-05 | 1974-09-10 | Snam Progetti | Curable,amorphous,olefinic terpolymers from alphamono olefins and polyenes |
| US4009200A (en) * | 1973-02-02 | 1977-02-22 | Uniroyal, Inc. | Hexahalo-1,4-dihydro-1,4-methano-napth-5,8-ylene acetates |
| JPS60152435A (ja) * | 1984-01-20 | 1985-08-10 | Dainippon Ink & Chem Inc | ２，３−ジアセチルノルボルナジエンとその製造法 |
| US7291689B1 (en) * | 2006-05-01 | 2007-11-06 | Seoul National University Industry Foundation | Thermally stable low dielectric norbornene polymers with improved solubility and adhesion property |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2750577A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8637561B2 (en) | 2009-02-17 | 2014-01-28 | Enanta Pharmaceuticals, Inc. | Linked diimidazole derivatives |
| EP2400846B1 (en) * | 2009-02-27 | 2016-10-05 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
| MY169311A (en) | 2009-03-27 | 2019-03-21 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| KR20180028070A (ko) * | 2009-05-13 | 2018-03-15 | 길리애드 파마셋 엘엘씨 | 항바이러스 화합물 |
| PT2432760E (pt) | 2009-05-18 | 2013-10-21 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx |
| AU2010253790A1 (en) * | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8221737B2 (en) * | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| NZ600608A (en) | 2009-12-18 | 2015-01-30 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| CA2794181A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| AR081848A1 (es) | 2010-06-09 | 2012-10-24 | Presidio Pharmaceuticals Inc | Inhibidores de la proteina ns5a del vhc |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012003642A1 (en) | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| CA2805440A1 (en) | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| BR112013002122A2 (pt) | 2010-07-26 | 2016-09-20 | Janssen R&D Ireland | derivados hetero-bicíclicos como inibidores de hcv |
| DK2599774T3 (en) * | 2010-07-29 | 2016-10-24 | Astellas Pharma Inc | DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| EP2621932A4 (en) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
| BR112013007696A2 (pt) | 2010-09-29 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, usos do referido composto e da referida composição |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| EP2651920A4 (en) | 2010-12-15 | 2014-12-17 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| EP2651926A4 (en) | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| CA2821973A1 (en) | 2010-12-16 | 2012-06-21 | Abbvie Inc. | Anti-viral compounds |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| CN102863428B (zh) * | 2011-07-09 | 2014-12-24 | 广东东阳光药业有限公司 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
| WO2013022810A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Chemical compounds |
| PH12014500311A1 (en) | 2011-08-08 | 2014-03-31 | Lupin Ltd | Antiviral compounds with a fused tricyclic ring |
-
2013
- 2013-08-02 TW TW102127866A patent/TWI610916B/zh active
- 2013-08-05 JP JP2015524600A patent/JP2015529652A/ja active Pending
- 2013-08-05 MY MYPI2014703257A patent/MY187617A/en unknown
- 2013-08-05 KR KR20157002654A patent/KR20150039200A/ko not_active Withdrawn
- 2013-08-05 SG SG11201406824XA patent/SG11201406824XA/en unknown
- 2013-08-05 CN CN201310337556.5A patent/CN103570693B/zh active Active
- 2013-08-05 BR BR112015000420A patent/BR112015000420A2/pt not_active IP Right Cessation
- 2013-08-05 RU RU2015107043A patent/RU2015107043A/ru not_active Application Discontinuation
- 2013-08-05 US US14/397,200 patent/US9309231B2/en not_active Expired - Fee Related
- 2013-08-05 WO PCT/CN2013/000915 patent/WO2014019344A1/en not_active Ceased
- 2013-08-05 EP EP13824843.0A patent/EP2880030B1/en not_active Not-in-force
- 2013-08-05 AU AU2013299246A patent/AU2013299246B2/en not_active Ceased
- 2013-08-05 CA CA2872118A patent/CA2872118A1/en not_active Abandoned
- 2013-08-05 MX MX2015001571A patent/MX2015001571A/es unknown
-
2014
- 2014-10-24 ZA ZA2014/07779A patent/ZA201407779B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529652A5 (cg-RX-API-DMAC7.html) | ||
| AU2018202581B2 (en) | Combination of direct acting antiviral agents and ribavirin for treating HCV patients | |
| US20130072528A1 (en) | Methods for Treating HCV | |
| RU2015107043A (ru) | Соединенные циклические соединения как ингибиторы вируса гепатита с (вгс) и их фармацевтическое применение | |
| AU2022209336A1 (en) | Methods for treating HCV | |
| US20130172240A1 (en) | Methods for treating hcv | |
| JP2013535487A5 (cg-RX-API-DMAC7.html) | ||
| WO2016134054A1 (en) | Anti-viral compounds | |
| EP2416765B1 (en) | Hcv inhibitor and therapeutic agent combinations | |
| US20140024613A1 (en) | Methods for Treating HCV | |
| US20160317603A9 (en) | Methods for Treating HCV | |
| WO2016134056A1 (en) | Anti-viral compounds | |
| WO2017040892A1 (en) | Anti-viral compounds | |
| WO2016182935A1 (en) | Anti-viral compounds | |
| WO2016134057A1 (en) | Anti-viral compounds | |
| WO2016182936A1 (en) | Anti-viral compounds | |
| US20180042982A1 (en) | Methods for Treating HCV | |
| WO2019074507A1 (en) | METHODS FOR THE TREATMENT OF HCV | |
| WO2019027694A1 (en) | METHODS OF TREATING HCV |